Evaluating PCSK9 Inhibitor Eligibility and Use in the Secondary Prevention of Acute Coronary Syndrome: A Single Centre Experience

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel medications for reducing low-density lipoprotein (LDL) cholesterol levels. In 2020, the Australian Pharmaceutical Benefits Scheme (PBS) began subsidising PCSK9 inhibitor use for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with LDL>2.6 mmol/L despite statin and ezetimibe therapy. This was expanded to LDL>1.8 mmol/L in 2022.